Skip to main content

Table 2 Antiretroviral treatments exposure during follow-up

From: Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting

 

eGFR (ml/min/1.73m2)

≥ 90

N = 28,289(81.4%)

60–89

N = 5645 (16.2%)

<  60

N = 819 (2.4%)

Total

N = 34,753

AZT based cART without PI, n(%)

13,737 (48.6)

2703 (47.9)

205 (25.0)

16,645 (47.9)

AZT based cART + PI, n(%)

2492 (8.8)

521 (9.2)

48 (5.9)

3061 (8.8)

TDF based cART without PI, n(%)

7708 (27.3)

1653 (29.3)

276 (33.7)

9637 (27.7)

TDF based cART + PI, n(%)

1645 (5.8)

284 (5.0)

2 (0.2)

1931 (5.6)

d4T based cART without PI, n(%)

1890 (6.7)

318 (5.6)

71 (8.7)

2279 (6.6)

d4T based cART + PI, n(%)

274 (0.9)

39 (0.7)

0

313 (0.9)

ABC or ddI based cART + PI, n(%)

395 (1.4)

57 (1.3)

16 (2.0)

468 (1.3)

ABC or ddI based cART without PI, n(%)

148 (0.5)

70 (1.0)

201 (24.5)

419 (1.2)

  1. eGFR estimated Glomerular Filtration Rate, cART combination Antiretroviral Therapy, AZT Zidovudine, PI protease inhibitor, TDF Tenofovir Disoproxil Fumarate, d4T Stavudine, ABC abacavir